Joint Pain News and Research

RSS

Patients once thought incurable can benefit from high-dose radiation therapy

In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer.

17 Oct 2018

Study sheds light on lupus's autoimmune origins in precursor cells

In the autoimmune disease systemic lupus erythematosus or SLE, the immune system produces antibodies against parts of the body itself. How cells that produce those antibodies escape the normal "checks and balances" has been unclear, but recent research from Emory University School of Medicine sheds light on a missing link.

11 Oct 2018

Scientists build model that predicts how temperature affects spread of Ross River virus

Scientists have built a model that predicts how temperature affects the spread of Ross River virus, a common mosquito-borne virus in Australia, according to a report in the journal eLife.

29 Aug 2018

Seeking solutions to treat scleroderma

It begins with cold hands. Not just put-on-some-gloves cold. Instead, the fingers overreact to cold by turning white or blue and may become numb or tingly.

17 Aug 2018

New study investigates whether nicotine could slow memory loss

Can nicotine slow or stop memory loss in people experiencing mild memory problems, or mild cognitive impairment? A new study being conducted at Georgetown University Medical Center aims to find out.

9 Aug 2018

Emerging Tech in Healthcare 2018

A recent workshop explored the latest technologies in healthcare, and how they can be used to address the demands of an ageing population.

8 Aug 2018

CHOP experts identify new autoimmune disorder along with personalized treatment for young patient

Elijah Patino is a happy, healthy seven-year-old now, but it took a while to get there. For much of his life, he had a mysterious disease that made it painful to eat and painful to play.

2 Aug 2018

Study finds sexual problems to be relatively common among middle-aged Canadians

At least one third of middle-aged Canadians experience sexual problems, according to a new U of G study. Researchers found nearly 40 per cent of women and almost 30 per cent of men between the ages of 40 and 59 face challenges in their sex lives.

2 Aug 2018

Researchers describe strategy used by Oropouche virus to replicate in human cells

The strategy used by the Oropouche virus to replicate in human cells has been described for the first time by researchers at the University of São Paulo in Brazil and international collaborators in an article published in the journal PLOS Pathogens.

31 Jul 2018

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

27 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

FDA approves first drug for treatment of adult AML patients with specific genetic mutation

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.

20 Jul 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

Researchers find that yellow fever and Asian tiger mosquitoes can carry new virus

A virus responsible for an illness outbreak in Venezuela is spreading to other parts of the Americas, says a University of Florida scientist who is closely monitoring the Mayaro virus.

18 Jul 2018

High opioid doses, concurrent sedative use are key factors for overdose risk in Medicaid recipients

Among Medicaid recipients taking prescription opioids, high opioid doses and concurrent treatment with benzodiazepine sedatives are among the key, potentially modifiable risk factors for fatal overdose, reports a study in the August issue of Medical Care.

13 Jul 2018

Study identifies constellation of metabolites linked to ME/CFS

A study led by researchers at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health has identified a constellation of metabolites related to myalgic encephalomyelitis/chronic fatigue syndrome.

10 Jul 2018

Zika virus-related pregnancy loss in humans may be more common than thought

Fetal death in utero occurred in more than one-fourth of monkeys infected in the laboratory with Zika virus in early pregnancy, according to new research published in Nature Medicine.

3 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

New study examines how the brain plays role in rheumatoid arthritis inflammation

In patients with chronic inflammatory conditions, such as rheumatoid arthritis, there has been limited understanding of how this inflammation affects the brain.

18 Jun 2018